Lorzaf Tablets 8Mg (1 Box = 1 Strip)(1 Strip = 10 Tablets)

Name: Lorzaf Tablets 8Mg (1 Box = 1 Strip)(1 Strip = 10 Tablets)
Brand: DYSON RESEARCH LABORATORIES
Price: 209.0

Brand : dyson research laboratories

Rs. 209.00

Rs. 220.00

|

QUICK DELIVERY

Lorzaf Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Lornoxicam

Used For

Pain & Inflammation

How it works

The mode of action of lornoxicam is partly based on inhibition of prostaglandin synthesis (inhibition of cyclo-oxygenase enzyme). The inhibition of cyclo-oxygenase does not result in an increase formation of leukotriene. As with other non-steroidal anti-inflammatory drugs the mechanism of the analgesic action of Lornoxicam has not been fully determined.

Lorzaf Tablets Usage And Safety

Dosage

Lornoxicam

Side Effects

Common : Abdominal pain, diarrhea, dyspepsia, nausea, vomiting, dizziness, headache, increase in blood urea nitrogen and creatinine levels, increase in serum transaminase levels and alkaline phosphatase level. Uncommon : Constipation, dysphagia, dry mouth, flatulence, gastritis, gastro- esophageal reflux, peptic ulceration and/or gastrointestinal bleeding, stomatitis, hemorrhoidal bleeding, thrombocytopenia, increased bleeding time, anemia, decrease in erythrocytes, hemoglobin, leucocytes, alopecia, dermatitis, pruritus, increased sweating ,rash urticaria, purpura, ecchymoses, insomnia, somnolence, malaise, weakness, flushing, aseptic meningitis, edema, hypertension, palpitations, tachycardia, hypotension, drowsiness, dizziness, vertigo, paraesthesia, tremor,taste perversion, dyspnoea, bronchospasm, cough, rhinitis, micturation disorder, agitation, depression, liver function abnormalities, myalgia, leg cramps, conjunctivitis, vision disorders, tinnitus, allergic reactions, alteration in appetite and weight changes.

Drug Interactions

Sulphonylureas , Other non-steroidal anti-inflammatory medicines and aspirin , loop diuretics and thiazide diuretics , ACE inhibitors , Lithium , Methotrexate , Cyclosporine , Cimetidine , Digoxin , CYP2C9 isoenzymes such as phenytoin, amiodarone, miconazole, tranylcypromine and rifampicin.

Indication

Lornoxicam is indicated for: Short term treatment of moderate pain, such as pain after dental surgery. - Short term treatment of mild to moderate pain associated with extra articular inflammation. - Treatment of pain associated with acute lumbo-sciatica. - Symptomatic treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis.

When not to Use

Lornoxicam is contraindicated in the following conditions: -Patients allergic to lornoxicam or any of the component of product. - Patients who have suffered from hypersensitivity reactions (Asthma, rhinitis, angioedema or urticaria) to other non steroidal anti-inflammatory medicines, including acetylsalicylic acid. - Patients with gastrointestinal bleeding, cerebrospinal bleeding or other bleeding disorders. - Patients with active peptic ulceration or with a history of recurrent peptic ulceration. - Patients with severe liver impairment. - Patients with severe renal impairment (serum creatinine >700µmol/L). - Patients with severe heart insufficiency. - Patients with severe thrombocytopenia. - Patients who are elderly (>65 years) and weighing less than 50kg and undergoing acute surgery.

Lorzaf Tablets Precautions

Precaution

Gastro-intestinal ulceration and bleeding in medical history: Clinical monitoring at regular intervals is recommended. Patients developing peptic ulceration and/or gastro-intestinal bleeding while taking lornoxicam should discontinue medicine administration with appropriate therapeutic actions being taken.

Lorzaf Tablets Warnings

Warning 1

Renal Impairment Patients with mild renal impairment (serum creatinine 150- 300µmol/L) should be monitored quarterly, patients with moderate renal impairment (serum creatinine 300- 700µmol/L) should be monitored at 1 to 2 month intervals. Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment.

Warning 2

Patients with coagulation disorders careful clinical monitoring and laboratory assessment is recommended (e.g., PTT).

Warning 3

Liver diseases (e.g. liver cirrhosis) Clinical monitoring and laboratory assessment at regular intervals is recommended (e.g., liver enzymes).

Download the Dvago App